Europe - EBR:BIOS - BE0974280126 - Common Stock
The current stock price of BIOS.BR is 0.0022 EUR. In the past month the price decreased by -8.33%. In the past year, price decreased by -57.69%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.08 | 48.01B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.86B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.35B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 23.93 | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 896.81M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 503.95M | ||
| FYB.DE | FORMYCON AG | N/A | 394.04M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
BioSenic SA is a biotech company engaged in the development of clinical assets . The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 3 full-time employees. The company went IPO on 2015-02-06. The firm develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. The company is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. The company also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).
BIOSENIC SA
Rue Granbonpre 11, Batiment H (bte 24)
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 3
Phone: 32493097366
BioSenic SA is a biotech company engaged in the development of clinical assets . The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 3 full-time employees. The company went IPO on 2015-02-06. The firm develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. The company is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. The company also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).
The current stock price of BIOS.BR is 0.0022 EUR.
BIOS.BR does not pay a dividend.
BIOS.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
BIOS.BR stock is listed on the Euronext Brussels exchange.
BIOSENIC SA (BIOS.BR) operates in the Health Care sector and the Biotechnology industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |